Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy.
OBJECTIVE
: To investigate the effect of lovastatin therapy and withdrawal on paraoxonase 1 (PON1) and arylesterase (ARE) activities, and low-density lipoprotein cholesterol (LDL-C) susceptibility to oxidation in people with type 2 diabetic nephropathy (T2DN).


METHODS
: Lovastatin (20mg/day) was administered to 30 people with T2DN for 90days and then withdrawn for 30days. PON1 and ARE activities were measured by the spectrophotometric method. Susceptibility of LDL-C to oxidation was determined as the production of conjugated dienes.


RESULTS
: After 90days of lovastatin intervention, PON1 and ARE activities and LDL-C lag phase were significantly increased (p=0.004, 0.002, and <0.001), while after 30days of lovastatin withdrawal, PON1 and ARE activities and LDL-C lag phase had not changed significantly.


CONCLUSIONS
: Lovastatin therapy improves PON1 and ARE activities, and LDL-C susceptibility to oxidation. Despite withdrawal of lovastatin, PON1 and ARE activities, and LDL-C susceptibility to oxidation remain unchanged in people with T2DN.
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Eastern Azerbaijan, Iran; Young Researchers Club, Islamic Azad University, Tabriz Branch, Tabriz, Eastern Azerbaijan, Iran.
Nariman
N
Nezami
Amir
A
Ghorbanihaghjo
Hassan
H
Argani
Javid
J
Safa
Nadereh
N
Rashtchizadeh
Amir Mansour
AM
Vatankhah
Behzad
B
Salari
Babak
B
Hajhosseini
D043303:Aryldialkylphosphatase / Q000378:metabolism; D008078:Cholesterol, LDL; D003928:Diabetic Nephropathies / Q000188:drug therapy; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism; D008148:Lovastatin / Q000627:therapeutic use; D010084:Oxidation-Reduction
D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; D008148:Lovastatin; D043303:Aryldialkylphosphatase